Morning Briefing
Summaries of health policy coverage from major news organizations
EpiPen Manufacturer To Bring $300 Generic Version To Market
The Associated Press: Mylan Launching Cheaper, Generic Version Of EpiPen
Mylan will start selling a cheaper version of its EpiPen after absorbing waves of criticism over a list price for the emergency allergy treatment that has grown to $608 for a two-pack, making it unaffordable for many patients. The drugmaker says it will launch in several weeks a generic EpiPen version that is identical to the branded option but will have a list price of $300 for a two-pack. (Murphy, 8/29)
The Wall Street Journal: Mylan To Launch Cheaper Generic EpiPen Alternative
Mylan NV on Monday said it would launch a generic alternative to EpiPen at a 50% discount after being criticized for dramatically raising the price of the lifesaving drug. The move, which analysts suspect could eat into Mylan’s EpiPen revenue, bodes well for insurers but underscores the shifting burden of health-care costs to patients. (Steele, 8/29)
USA Today: Mylan To Offer Generic EpiPen For 50% Less
The generic version "will be identical to the branded product, including device functionality and drug formulation," Mylan said in a statement. It will hit shelves within several weeks at a list price of $300 for a two-pack carton in dosages of either 0.15 milligrams or 0.30 mg, the company said. (Bomey, 8/29)
CNN Money: Generic EpiPen At $300 Coming Soon, As Mylan Responds To Outrage
The surprise move is the latest attempt by Mylan to silence the uproar ignited by a more than 400% increase in EpiPen prices. The launch comes ahead of looming competition from Teva Pharmaceuticals, which is hoping to launch a generic EpiPen of its own as early as next year, pending FDA approval. (Egan, 8/29)
